

**AMENDMENT TO THE CLAIMS:**

Claim 1 (cancelled)

2. (Currently amended) A formulation comprising Apo-2 ligand trimers and ~~one or more divalent metal ions comprising zinc or cobalt~~, wherein the concentration of said ~~one or more divalent metal ions~~ zinc present in the formulation is ~~at a <2X molar ratio to said Apo-2 ligand~~ an amount effective to stabilize the Apo-2 ligand trimers in the formulation and the Apo-2 ligand trimers comprises ~~a~~ polypeptides selected from the group consisting of:

- (a) a polypeptide having amino acid residues 1 to 281 of Figure 1 (SEQ ID NO:1);
- (b) a polypeptide having amino acid residues 114 to 281 of Figure 1 (SEQ ID NO:1);
- (c) a fragment of the polypeptide of (a) or (b) which induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor; and
- (d) a polypeptide having at least 80% identity to the polypeptide of (a) or (b), and induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor.

Claim 3 (Cancelled)

4. (Currently amended) The formulation of claim 3 2 wherein said zinc is selected from the group consisting of zinc chloride, zinc acetate, zinc sulfate, zinc carbonate and zinc citrate.

5. (Previously presented) The formulation of claim 2 wherein said formulation is a pharmaceutically acceptable formulation.

6. (Previously presented) The formulation of claim 2 wherein said Apo-2 ligand comprises amino acids 114 to 281 of Figure 1 (SEQ ID NO:1).

7. (Previously presented) The formulation of claim 2 wherein said Apo-2 ligand comprises amino acids 1 to 281 of Figure 1 (SEQ ID NO:1).

8. (Previously presented) The formulation of claim 2 wherein said formulation has a pH of about 6 to about 9.

9. (Original) The formulation of claim 8 wherein said formulation has a pH of about 7 to about 7.5.

10. (Previously presented) The formulation of claim 2 wherein said formulation is an aqueous formulation.

11. (Previously presented) The formulation of claim 2 wherein said formulation is a lyophilized formulation.

Claims 12-49 (Cancelled)

50. (Currently amended) A pharmaceutically acceptable formulation comprising Apo-2 ligand trimers and zinc, wherein the concentration of said zinc present in the formulation is ~~at a <2X molar ratio to said Apo-2 ligand~~ an amount effective to stabilize the Apo-2 ligand trimers in the formulation and the Apo-2 ligand trimers comprises ~~a~~ polypeptides selected from the group consisting of:

- (a) a polypeptide having amino acid residues 1 to 281 of Figure 1 (SEQ ID NO:1);
- (b) a polypeptide having amino acid residues 114 to 281 of Figure 1 (SEQ ID NO:1);
- (c) a fragment of the polypeptide of (a) or (b) which induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor; and
- (d) a polypeptide having at least 80% identity to the polypeptide of (a) or (b), and induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor.

51. (Original) The formulation of claim 50 wherein said zinc is selected from the group consisting of zinc chloride, zinc acetate, zinc sulfate, zinc carbonate, and zinc citrate.

52. (Previously presented) The formulation of claim 50 wherein said formulation has a pH of about 6 to about 9.

53. (Previously presented) The formulation of claim 50 wherein said formulation has a pH of about 7 to about 7.5.

54. (Previously presented) The formulation of claim 50 wherein said formulation is a lyophilized formulation.

Claims 55-60 (Cancelled)